Bronstein, Gewirtz & Grossman, LLC: Investigating Potential Claims against Lifecore Biomedical, Inc.
On March 30, 2025, Bronstein, Gewirtz & Grossman, LLC, a prominent securities litigation firm based in New York, announced that it is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (Lifecore or the Company) (NASDAQ: LFCR). The investigation comes in response to recent developments regarding allegations of potential securities law violations at the biotech company.
Background on Lifecore Biomedical, Inc.
Lifecore Biomedical is a biotechnology company that specializes in the development, manufacturing, and supply of medical devices, including tissue-based products and advanced wound care solutions. The company’s mission is to provide high-quality, innovative solutions that improve patient outcomes and enhance the lives of healthcare providers and their patients.
Allegations and Investigation
The investigation by Bronstein, Gewirtz & Grossman, LLC, centers around allegations of potential securities law violations by Lifecore. Specifically, the firm is looking into whether the Company and certain of its executives and directors made false and misleading statements regarding the Company’s business, operations, and financial condition.
Impact on Individual Investors
Individual investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information about the investigation. The potential impact on these investors could be significant if it is determined that the Company and its executives and directors violated securities laws. In such a case, investors may be able to recover their losses through a securities class action lawsuit.
Impact on the World
The potential impact of this investigation on the biotech industry and the world at large could be far-reaching. If it is found that Lifecore and its executives and directors violated securities laws, it could lead to increased scrutiny of other biotech companies and their business practices. This, in turn, could negatively impact investor confidence in the industry and potentially lead to decreased investment in biotech companies.
Conclusion
The investigation by Bronstein, Gewirtz & Grossman, LLC, into potential securities law violations at Lifecore Biomedical, Inc., is a significant development for the biotech industry and individual investors. The potential impact on investors who purchased Lifecore securities prior to October 7, 2020, could be substantial if it is determined that the Company and its executives and directors violated securities laws. Additionally, the impact on the biotech industry and the world at large could be far-reaching if increased scrutiny leads to decreased investor confidence and decreased investment in the sector.
If you are an individual investor who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, you are encouraged to visit the firm’s site at bgandg.com/LFCR for more information about the investigation and how to assist in the process.
